Section Review Oncologic, Endocrine & Metabolic: Farnesyl-protein transferase inhibitors in early development
- 1 December 1996
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 5 (12) , 1589-1599
- https://doi.org/10.1517/13543784.5.12.1589
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Review Oncologic, Endocrine & Metabolic: Inhibitors of protein farnesylation: A new approach to cancer chemotherapyExpert Opinion on Therapeutic Patents, 1995
- Novel Tricyclic Inhibitors of Farnesyl Protein TransferasePublished by Elsevier ,1995
- Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I InhibitorPublished by Elsevier ,1995
- Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf ComplexesPublished by Elsevier ,1995
- Pseudodipeptide Inhibitors of Protein FarnesyltransferaseJournal of Medicinal Chemistry, 1995
- Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in VitroJournal of Biological Chemistry, 1995
- Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeuticCell, 1994
- Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal CellsScience, 1993
- Selective Inhibition of ras -Dependent Transformation by a Farnesyltransferase InhibitorScience, 1993
- ras GENESAnnual Review of Biochemistry, 1987